Pathios Therapeutics

Pathios Therapeutics is a clinical-stage drug discovery company developing small molecule inhibitors of GPR65, a pH-sensing G protein-coupled receptor that drives immunosuppressive polarisation of tumour-associated macrophages in the acidic tumour microenvironment.

By blocking GPR65, Pathios aims to restore anti-tumour immune responses in cancers resistant to existing immunotherapies.

Its lead programme is advancing towards the clinic across multiple solid tumour indications. The company also explores GPR65 inhibition in autoimmune disease.